It was no earlier than 1986 that T helper (Th)1 and Th2 cells were described for the first time, opening the field of lymphocyte diversity and the investigation of the physiopathology of inflammatory diseases such as atopic dermatitis and psoriasis. Since that time, much research has been carried out showing a very complex communication network leading to inflammatory responses. Nowadays, understanding the cellular and molecular components of the inflammatory network and of the different crosstalks not only for groups of diseases but also for the individual patient is mandatory for developing and personalizing treatments. The aim of the present proceeding was to provide an update concerning some of the most recent molecular and cellular discoveries in inflammatory skin diseases and especially of AD.
Introduction
It was no earlier than 1986 that Mosmann et al. 1 described the type T helper cells Th1 and Th22 for the first time, thereby opening the field of lymphocyte diversity and the investigation of the physiopathology of inflammatory diseases such as atopic dermatitis (AD). Five years later, Reinhold et al. 2 described the functional features of skin-infiltrating lymphocytes in AD.
Since that time, much research has been carried out showing a very complex communication network leading to inflammatory responses. In parallel, research in the domain of the management of AD through targeting cytokines has progressed rapidly and very recently, a human monoclonal antibody acting against interleukin-4 (IL-4) receptor-alpha by inhibiting the signalling of IL-4 and IL-13 has provided promising results in the management of the disease. 3 The aim of the present proceeding was to provide an update concerning some of the most recent molecular and cellular discoveries in inflammatory skin diseases.
Methodology
The author conducted a literature review using the PubMed database, selecting specific topics in order to illustrate the complexity of immune networks in skin inflammation along two lines: (i) one given cytokine can have different functions in different microenvironments and thus contributes to a diversity of inflammatory diseases; (ii) one given disease type involves a diversity of molecular and cellular players, each one of them constituting potential therapeutic targets.
Cytokines in skin inflammation: functional plasticity and pleiotropy
Cytokines are communication molecules that determine and modulate the biological outcome of the adaptive immune response to specific antigens and the response to inflammatory stimuli. [4] [5] [6] To date, many cytokines have been identified, comprising the large interleukin family. They play an important role in the communication between cells, cell growth, differentiation and motility, including tumour necrosis factor-a (TNF-a) and thymic stromal lymphopoietin (TSLP). Due to their plasticity and functional pleiotropy, cytokines may be involved in different diseases and especially trigger inflammatory responses leading to different inflammatory skin diseases.
The following proceeding focuses on two cytokines, TNF-a and TSLP, in order to illustrate how a single molecule can play different functions in different types of inflammation.
Already in 1992, TNF-a was suggested to be associated with increased plasma histamine concentration and was proposed to be involved in the pathophysiology of AD. 8 It is certainly the most studied cytokine, due to its increased expression in skin lesions and in the serum of patients with AD or psoriasis and, above all, due to the therapeutic efficacy of its specific inhibitors. [9] [10] [11] [12] [13] [14] Thymic stromal lymphopoietin (TSLP) is a sensitive marker of epithelial inflammation and the effects in the epidermal barrier. [15] [16] [17] [18] [19] Moreover, it is an important trigger in the pathogenesis of both AD and asthma, in which it promotes CD4+ T-cell polarization into T helper type 2 (Th2) cells. [19] [20] [21] [22] [23] [24] [25] [26] [27] In AD, it targets dendritic cells and innate lymphoid cells and elicits IL-33-independent innate lymphoid cell responses leading to skin inflammation. 21, 28, 29 However, in AD, TSLP is not only a mediator of inflammation, it also mediates pruritus, an important symptom of this condition. 30, 31 Within the complex psoriasis network, TSLP increases the production of IL-23 in a signal transducer and activator of transcription 6-independent manner (Fig. 1) . Moreover, it regulates dendritic cell migration and is expressed in head and neck cancer, although with a functionally truncated pathway. 28, 32, 33 Recent research showed that a human anti-TSLP monoclonal immunoglobulin G2k was able to bind human TSLP, preventing receptor interaction and reducing allergen-induced bronchoconstriction and indexes of airway inflammation before and after allergen challenge. However, more research remains to be carried out to confirm its efficacy in AD and allergies. 34 To summarize, recent studies have highlighted the functional plasticity of cytokines and their possible involvement in the diversity of inflammatory diseases. This illustrates the importance of generating specific knowledge for each molecule in different inflammatory contexts.
Inflammatory skin diseases: complex networks and molecular targets
Hereafter, primarily AD, but also some other skin inflammatory conditions will be discussed, in order to review some recent discoveries in the complexity of the cellular and molecular network underlying the disease.
Atopic dermatitis
In AD, the skin epithelial barrier, as well as the innate and adaptive immunity, is involved. At the skin epithelial barrier level, TSLP, IL-25 and IL-33 are produced by keratinocytes, while at the innate immunity level, TSLP, tumor necrosis factor-alpha (TNF-a), IL-5 and IL-13 are produced by mast cells. Finally, CD4+ T helper cells involved in the adaptive immunity produce IL-21, IL-31, IL-4, IL-17 and IL-25. All may be potential therapeutic targets in AD and are involved through multiple functional interactions. 35 and Th22 cells are also found in the AD microenvironment, but their contribution to disease pathogenesis is less clear, with possible intricate pathways between allergy and bacterial infection. 38 Moreover, the disease stage impacts on the cytokine and inflammatory network. Especially in skin conditions such as AD, a non-lesional, an acute or a chronic stage can be observed. Each stage presents with different cytokines triggering different signs and symptoms of the disease. 39, 40 Therefore, prior to targeting any of the potentially involved cytokines, it is important to understand the complexity of the cellular crosstalks, checkpoints and disease stages. To date, it is accepted that environmental factors play an important role in the pathophysiology of AD, with allergens being at the forefront. However, microbes such as Staphylococcus aureus and Malassezia spp. have also been reported to trigger AD and to induce Th2 cytokine production. Investigating the human skin microbiome, the interplay between host and microbes has therefore become a major focus in the field. [41] [42] [43] [44] [45] Understanding the ecosystem of the skin, the role of microbes and external factors that impact the balance of the skin barrier, or skin homeostasis, more thoroughly, may provide a better understanding of the pathophysiology of AD and thereby open new treatment perspectives.
Psoriasis
Psoriasis is a chronic, immune-mediated inflammatory skin disease sharing certain pathways such as TSLP, Th17 or TNF with AD. 46, 47 Histological changes observed within lesional skin include (i) a thickened epidermis from rapid keratinocyte proliferation and aberrant differentiation, (ii) a reduced or absent granular layer, (iii) marked dilatation of blood vessels in the papillary dermis and (iv) dense clusters of inflammatory cells composed of Th cells and dendritic cells in the dermis, as well as CD8+ Th cells and neutrophils in the epidermis. 48 They all have been well described for decades and include multiple elements that indicate immune-mediated inflammation. 49 The understanding of the pathogenesis of psoriasis was advanced by the discovery of Th17 cells which regulate the innate and adaptive immunity. The pro-inflammatory cytokine IL-17A is the primary effector of Th17 cells, but it is also released by cd T cells, neutrophils and, possibly, mast cells. 50 While in chronic or plaque-type psoriasis TNF/IL-17 plays a major role, interferon a (INF-a) seems to play the main role in acute or unstable, erythrodermic paradoxical psoriasis. Conversely, IL-36 and IL-1 trigger papulopustular or granulopustular psoriasis.
Currently, treatment perspectives include the blocking of the TNF, IL-23 and IL-17/17R pathway (chronic psoriasis), the use of cyclosporine, UV light, steroids, vitamin D or blocking of interferon/plasmacytoid dendritic cell pathway (acute psoriasis) or the use of cyclosporine, infliximab, retinoids, methotrexate or blocking of the IL-1 and IL-36 pathway (pustular psoriasis). 57, [67] [68] [69] To summarize, as for atopic dermatitis, the complexity of underlying mechanisms suggests multiple new therapeutic targets in psoriasis.
Inflammasomopathies
Inflammasomes are intracellular multiprotein complexes that are involved in innate immune response. Skin symptoms are central features of monogenic inflammasomopathies, such as cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean fever (FMF), Schnitzler syndrome, hyper-IgD syndrome (HIDS), PAPA syndrome and deficiency of IL-1 receptor antagonist (DIRA). 70 The pathway common to all inflammasomes comprises the activation of caspases and IL-1b, along with possible cell death due to pyroptosis. Despite a growing body of research investigating the structure and function of the inflammasome in animal models, there is still limited evidence of identifying inflammasome components in human physiology and diseases.
Inflammasome components have been identified in several human peripheral and brain tissues using both in vivo and ex vivo work, and the inflammasome complex has been shown to be associated with several genetic and acquired inflammatory disorders.
Modulation of the inflammasome has been proposed as a novel treatment possibility for several of these diseases and there are currently clinical trials ongoing to test this hypothesis. 71 
Sporadic pyoderma gangrenosum
Pyoderma gangrenosum (PG) is a non-infectious reactive neutrophilic dermatosis typically starting with pustules which rapidly evolve to painful ulcers of variable size and depth with undermined violaceous borders. 72 The pathogenesis of PG remains elusive even though IL-1b plays a key role. 72, 73 Emerging therapies include the use of platelet-derived growth factor and cell culture grafts when re-epithelialization is slow, or the TNF-a blocking agent infliximab for refractory diseases. Recently, canakinumab was shown to be an interesting therapeutic option in steroid refractory disease. 73 
Interferonopathies
Auto-inflammatory syndromes and diseases are a group of disorders of the innate immunity. 74 Type I interferons mediate immune defence against viral infections. The induction of type I interferons has stimulating and modulating effects on the innate and adaptive immune systems, thereby reducing tolerance against self-antigens. These disorders can be the result of genetic defects leading to an inadequate activation of the type I interferon system and are collectively referred to as type I or monogenic interferonopathies. While the clinical spectrum of type I interferonopathies is broad and heterogeneous, neurological and cutaneous symptoms are the most frequent manifestations. Some clinical and genetic features of type I interferonopathies are shared by multifactorial diseases, such as systemic lupus erythematosus and systemic vasculitis. 75, 76 Current treatment consists in systemic steroids, disease-modifying antirheumatic drugs (DMARDs) and inhibitors of the Janus kinase/signal transducer and activator of transcription (JAK-STAT). 77, 78 Future treatments may include anti-interferons such as anti-IFN-a Ab and anti-IFNR Ab.
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Conclusion
Recent advances in the mechanisms underlying skin inflammation highlight the importance of two levels of complexity both being of high clinical relevance. The same cytokine can be involved in multiple disease types but may have different functions, so should be considered in a different manner for each specific clinical setting. On the other hand, a single inflammatory disease involves multiple cellular and molecular components, each of them constituting potential therapeutic targets. However, their respective contribution to the disease in individual patients may vary. Hence, understanding the cellular and molecular components of the inflammatory network and of the different crosstalks, not only for groups of diseases but also for the individual patient, is mandatory for developing and personalizing treatments.
Future challenges will be the elucidation of the most important mediators of inflammation among the different molecular and cellular players in order to specifically target each disease.
